Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
Authors
Keywords
-
Journal
Translational Psychiatry
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-11-13
DOI
10.1038/s41398-021-01709-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
- (2021) Shi-Dong Chen et al. Translational Psychiatry
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
- (2020) Elisabeth H. Thijssen et al. NATURE MEDICINE
- Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography
- (2020) Pierre-François Meyer et al. JAMA Neurology
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
- (2020) Thomas K Karikari et al. LANCET NEUROLOGY
- Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
- (2020) James D. Doecke et al. NEUROLOGY
- Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
- (2020) Niklas Mattsson-Carlgren et al. Science Advances
- Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
- (2019) Andrea Vergallo et al. Alzheimers & Dementia
- Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia
- (2019) Clifford R. Jack et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study
- (2019) Jin-Tai Yu et al. Alzheimers & Dementia
- Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a “gray zone”?
- (2019) Kevin McRae-McKee et al. Alzheimers & Dementia
- Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
- (2019) Sebastian Palmqvist et al. EMBO Molecular Medicine
- Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
- (2019) Virginia Pérez-Grijalba et al. Alzheimers Research & Therapy
- Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography
- (2018) Michelle M. Mielke et al. Alzheimers & Dementia
- CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
- (2018) Oskar Hansson et al. Alzheimers & Dementia
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer’s Disease
- (2018) Che-Chuan Yang et al. JOURNAL OF ALZHEIMERS DISEASE
- Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
- (2018) Chin-Hsien Lin et al. Frontiers in Aging Neuroscience
- Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease
- (2018) Jong-Chan Park et al. BRAIN
- Blood-Brain Barrier: From Physiology to Disease and Back
- (2018) Melanie D. Sweeney et al. PHYSIOLOGICAL REVIEWS
- Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
- (2017) Harutsugu Tatebe et al. Molecular Neurodegeneration
- Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid
- (2016) Tobias Bittner et al. Alzheimers & Dementia
- In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
- (2016) Hanna Cho et al. ANNALS OF NEUROLOGY
- Establishment and Dysfunction of the Blood-Brain Barrier
- (2015) Zhen Zhao et al. CELL
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- Comparing predictors of conversion and decline in mild cognitive impairment
- (2010) S. M. Landau et al. NEUROLOGY
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
- (2009) Susan M. Landau et al. NEUROBIOLOGY OF AGING
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now